Mesalazine as a new therapeutic option for chronic idiopathic urticaria

References

• Najib U, Sheikh J. The spectrum of chronic urticaria. Allergy Asthma Proc 2009;30:1–10.
   PubMed Web of Science ®Google Scholar
• Kaplan AP, Greaves M. Pathogenesis of chronic urticaria. Clin Exp Allergy 2009;39:777–787.
   PubMed Web of Science ®Google Scholar
• O'Donnel BF, Lawlor F, Simpson J, The impact of chronic urticaria on the quality of life. Br J Dermatol 1997;136:197–201.
   PubMedGoogle Scholar
• Poon E, Seed PT, Greaves MW, The extent and nature of disability in different urticarial conditions. Br J Dermatol 1999;140:667–671.
   PubMed Web of Science ®Google Scholar
• Khan DA. Chronic urticaria: diagnosis and management. Allergy Asthma Proc 2008;29:439–46.
   PubMed Web of Science ®Google Scholar
• Lourenço FD, Azor MH, Santos JC, Prearo E, Maruta CW, Rivitti EA, Activated status of basophils in chronic urticaria leads to interleukin-3 hyper-responsiveness and enhancement of histamine release. Br J Dermatol 2008;158(5):979–986.
   PubMedGoogle Scholar
• Młynek A, Maurer M, Zalewska A. Update on chronic urticaria: focusing on mechanisms. Curr Opin Allergy Clin Immunol 2008;8(5):433–437.
   PubMedGoogle Scholar
• Zuberbier T, Bindslev-Jensen C, Canonica W, Grattan CE, Greaves MW, Henz BM, EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy. 2006;61(3):316–320.
   PubMedGoogle Scholar
• Morgan M, Khan DA. Therapeutic alternatives for chronic urticaria: an evidence-based review, Part 2. Ann Allergy Asthma Immunol 2008;100(6):517–26; quiz 526-528, 544.
   PubMedGoogle Scholar
• Morgan M, Khan DA. Therapeutic alternatives for chronic urticaria: an evidence-based review, Part 1. Ann Allergy Asthma Immunol 2008;100(5):403–411; quiz 412-414, 468.
   PubMedGoogle Scholar
• Engler RJ, Squire E, Benson P. Chronic sulfasalazine therapy in the treatment of delayed pressure urticaria and angioedema. Ann Allergy Asthma Immunol 1995;74(2):155–9.
   PubMedGoogle Scholar
• McGirt LY, Vasagar K, Gober LM, Saini SS, Beck LA. Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine. Arch Dermatol 2006;142(10):1337–1342.
   PubMedGoogle Scholar
• Sweetman SC. Martindale: The complete drug reference, 36th ed. London: Pharmaceutical Press; 2009.
   Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19(3):210–216.
   PubMed Web of Science ®Google Scholar
• Lennox RD, Leahy MJ. Validation of the dermatology life quality index as an outcome measure for urticaria-related quality of life. Ann Allergy Asthma Immunol 2004;93(2):142–146.
   PubMedGoogle Scholar
• Finlay AY, Khan GK. Dermatology life quality index. Available at: http://www.dermatology.org.uk/downloads/dlqifarsi.doc.
   Google Scholar
• Aghaei S, Sodaifi M, Jafari P, Mazharinia N, Finlay AY. DLQI scores in vitiligo: reliability and validity of the Persian version. BMC Dermatol 2004;4:8.
   PubMedGoogle Scholar
• Nettis E, Colanardi MC, Barra L, Ferrannini A, Vacca A, Tursi A. Levocetirizine in the treatment of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Br J Dermatol 2006;154(3):533–538.
   PubMedGoogle Scholar
• Bharti R. Mesalazine in treatment of psoriasis. Indian J Dermatol Venereol Leprol 1996;62:231–232.
   PubMedGoogle Scholar
• Di Lorenzo G, Pacor ML, Mansueto P, Esposito-Pellitteri M, Ditta V, Lo Bianco C, Is there a role for antileukotrienes in urticaria? Clin Exp Dermatol 2006;31(3):327–334.
   PubMedGoogle Scholar
• Allgayer H. Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther 2003;18(Suppl 2):10–14.
   PubMed Web of Science ®Google Scholar
• Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K. Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol 2000;95(12):3452–3457.
   PubMedGoogle Scholar
• Stevens C, Lipman M, Fabry S, Moscovitch-Lopatin M, Almawi W, Keresztes S, 5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells. J Pharmacol Exp Ther 1995;272(1):399–406.
   PubMedGoogle Scholar
• Greenfield SM, Hamblin AS, Shakoor ZS, Teare JP, Punchard NA, Thompson RP. Inhibition of leucocyte adhesion molecule upregulation by tumor necrosis factor alpha: a novel mechanism of action of sulphasalazine. Gut 1993;34(2):252–6.
   PubMedGoogle Scholar
• Punchard NA, Greenfield SM, Thompson RPH. Mechanism of action of 5-aminosalicylic acid. Mediators Inflamm 1992;1(3):151–165.
   PubMedGoogle Scholar
• Haskó G, Szabó C, Németh ZH, Deitch EA. Sulphasalazine inhibits macrophage activation: inhibitory effects on inducible nitric oxide synthase expression, interleukin-12 production and major histocompatibility complex II expression. Immunology 2001;103(4):473–478.
   PubMedGoogle Scholar
• Fox CC, Moore WC, Lichtenstein LM. Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci 1991;36(2):179–184.
   PubMedGoogle Scholar